A single agent-combination hybrid phase I, dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous AVE0005 [aflibercept] administered every 2 weeks in combination with oral S-1 in patients with advanced solid malignancies.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Aflibercept (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Sanofi
- 06 Jan 2020 Results published in the Investigational New Drugs
- 25 Jan 2011 Actual end date (January 2011) added as reported by ClinicalTrials.gov.
- 25 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.